Analysis
Harvard Management Company's latest 13F filing, released Friday, shows a $2.2 billion stake in SpaceX -- the single largest position in the endowment's disclosed U.S. equity holdings, according to Fortune. Harvard's disclosed U.S. equities book totals $4.3 billion, meaning SpaceX alone accounts for roughly half of everything the endowment reports owning in domestic public stocks.
## A decade-old venture bet, now a public-market headline The position isn't new money chasing a hot IPO. Harvard's SpaceX exposure traces back to venture-stage investments made through outside fund managers, in some cases more than a decade ago, long before SpaceX's June IPO priced the company at $135 a share and a $1.77 trillion valuation -- the largest IPO ever completed. SpaceX traded around $140 the day Harvard's filing landed, putting the company's market value above $1.8 trillion and turning what was once an illiquid, marked-to-model private position into one of the largest and most liquid single-stock bets in any university endowment's public book.
Harvard isn't alone. Other endowments disclosed comparable SpaceX exposure acquired the same way -- through venture funds that got early access years before a public listing was on the table:
“## What the filing actually tells you, and what it doesn't A 13F filing discloses long U.S.”
- Harvard -- $2.2B stake, roughly 4% of its $57B total endowment (as of June 2025)
- University of California -- ~$1B SpaceX position disclosed by its investment arm
- University of North Carolina -- substantial SpaceX-linked gains reported in its endowment
- Washington University in St. Louis -- substantial SpaceX-linked gains reported in its endowment
That's a genuinely large single-name concentration for an institution that has historically prized diversification across asset classes. Pulse has previously covered SpaceX's rapid post-IPO trajectory, including its $60 billion Cursor acquisition closing this same week.
## What the filing actually tells you, and what it doesn't A 13F filing discloses long U.S. equity positions as of quarter-end; it says nothing about cost basis, when Harvard's underlying venture funds first got SpaceX exposure, or what percentage of that exposure Harvard has already sold down since the IPO priced in June. Endowments routinely use post-IPO windows to de-risk concentrated positions once lockups expire, and it's entirely possible Harvard's $2.2 billion mark today reflects a position that was larger before the IPO and has already been partially trimmed -- or one that Harvard is deliberately holding through, betting SpaceX's trajectory continues. The filing alone can't distinguish between those two stories.
What it does confirm is how much value university endowments extracted from early access to SpaceX specifically, at a moment when critics of the endowment model have argued that illiquid venture allocations tie up capital for years without proof of payoff. SpaceX is close to the best-case version of that thesis playing out -- a venture-stage bet that matured into the largest IPO in history and a trillion-dollar-plus public company. Whether Harvard's other illiquid venture exposure eventually produces anything close to a comparable outcome is a different, far less certain question that this filing doesn't answer.
The next disclosure to watch is Harvard's 13F for the quarter SpaceX's post-IPO lockup expires in full -- that filing will show whether Harvard is a long-term holder or was simply waiting for liquidity to trim.
